Shares of Morepen Laboratories fell 3% in early trade on Monday after the company released its consolidated financial results for the fourth quarter of the financial year 2024-25 (Q4 FY25). The market reaction followed a mixed set of numbers, with revenue growth offset by a decline in profitability. As of 9:19 AM, the shares were trading 3.05% lower at Rs 58.52.
On a year-on-year consolidated basis, the company reported a 10.1% increase in revenue, rising to ₹465.8 crore from ₹423 crore in the same quarter last year.
However, profitability indicators weakened during the period. EBITDA declined by 12.6%, falling to ₹42.3 crore from ₹48.4 crore, with EBITDA margin compressing to 9.1% from 11.4% a year ago. Net profit also saw a notable decline of 29.3%, coming in at ₹20.3 crore compared to ₹28.7 crore in the corresponding quarter of the previous year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
